The article by Tandon et al.1 in this issue of the Journal highlights one of the most important areas of research in clinical oncology today — the search for better means of predicting the risk of a recurrence in women after local and regional treatment of breast cancer that appears to be localized. The population of women to whom such information is directly applicable is large; an estimated 150,000 women will be given a diagnosis of breast cancer in 1990 (Silverberg E: personal communication), and about half will have disease that is apparently confined to the breast, with no axillary-lymph-node . . .
No takes yet. Share an insight, caveat, or question.
James N. Ingle (1990) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: